Quick answer
ADHD in women is real, and some women are genuinely missed. But trouble focusing, disorganization, overwhelm and strong emotions have many possible causes, including medical conditions, hormonal changes, sleep problems, medication side effects, alcohol or other substances, anxiety, depression and other mental health conditions, and stress. A diagnosis depends on symptoms that started in childhood, show up in more than one part of life, and aren't better explained by another condition. Feeling more focused on a stimulant doesn't prove ADHD.
Key takeaways
- Trouble focusing and overwhelm are real, but they have many possible causes besides ADHD, and more than one can be true at once.
- ADHD starts in childhood; symptoms that were there all along can become noticeable in adulthood, but in a 2018 North American study, most people who first screened positive for late-onset ADHD didn't have it after careful assessment.
- Feeling more focused on a stimulant doesn't prove ADHD, and people may believe they're doing better when tests show little change.
- Before deciding about ADHD, a careful evaluation looks at mood, sleep, medical health, substances and reliable information about your childhood.
If you’re struggling to focus, stay organized or manage strong emotions, those struggles are real and worth taking seriously. But they have many possible causes, and a 2024 U.S. review in American Family Physician notes a “substantial overlap of symptoms” between adult ADHD and other conditions.
Some women with ADHD are genuinely missed. NIMH notes that ADHD symptoms among girls and women are especially likely to have been missed in childhood. In older U.S. survey data (published in 2006), about 1 in 8 women with ADHD (ages 18 to 44) were treated in the past year, a rate similar to men’s. Stimulant prescribing to adult women then rose sharply from 2020 to 2021, according to CDC data on commercially insured adults. Whether that rise reflects better recognition or overdiagnosis is still debated.
Others may be given an ADHD diagnosis when something else better explains their symptoms. A thorough evaluation, with a full history and information from people who know you, can help find ADHD that was missed and other explanations when ADHD isn’t the cause. Our adult ADHD page explains how we care for ADHD in adults.
What Else Can Look Like ADHD
Trouble focusing, forgetfulness and restlessness have many possible causes, and several conditions can mimic ADHD, the American Psychiatric Association notes. They include:
- Medical: perimenopause and PMDD; thyroid conditions, including an overactive thyroid; anemia or low iron; low vitamin B12; low blood sugar (which can cause confusion or trouble thinking clearly) and diabetes (a Canadian review), which also occurs more often in adults with ADHD (a Swedish study); a head injury or concussion; long COVID; chronic fatigue syndrome (ME/CFS); chronic pain (an Irish review).
- Sleep: too little sleep, insomnia, sleep apnea, restless legs syndrome and shift work.
- Medication side effects: steroids; older, sedating antihistamines (which can cause confusion or trouble thinking clearly); some seizure medicines; overuse of opioid pain medicines or sleeping pills; benzodiazepines, and stopping them.
- Substances: alcohol, cannabis, nicotine withdrawal, too much caffeine and other drugs.
- Mental health: depression, including postpartum depression; anxiety; bipolar disorder; trauma and PTSD; OCD and borderline personality disorder (a European expert consensus); grief; burnout (a Greek review); learning disorders and autism (the diagnostic manual used by U.S. clinicians, DSM-5-TR, lists both among the conditions to tell apart from ADHD).
- Life: chronic stress and constant phone notifications, which can repeatedly interrupt focus.
More than one of these can be true at once. Many of these conditions also commonly occur alongside ADHD, so having one doesn’t rule ADHD out, the 2024 review in American Family Physician and an international review led by U.S. researchers note. For many women, stress includes the load at home: the bulk of household, parenting and caregiving duties often falls to women, a UK-led international consensus notes. A heavy load at home can add to stress and, for women with ADHD, worsen day-to-day difficulties. Our posts on ADHD or burnout and Do I have ADHD, or am I just overwhelmed? go deeper.
Anxiety and depression also often come with ADHD. An international review of large studies found that adults with ADHD had about five times the odds of an anxiety disorder and about four and a half times the odds of major depression compared with adults without ADHD. That held for both men and women; as in the general population, anxiety and depression were more common in women.
What Has to Be True for It to Be ADHD
No single test can diagnose ADHD, the CDC explains. In plain terms, a diagnosis depends on a few things:
- Symptoms started in childhood, before age 12, even if they weren’t recognized or diagnosed then.
- They show up in more than one part of life, such as work, home and relationships.
- They cause real problems in daily life.
- They aren’t better explained by another mental health condition or substance use; a medical evaluation checks for physical causes.
Reliable information about childhood matters, and it can be hard to get: adults often have trouble recalling when their problems began, a U.S. review of the diagnostic criteria notes.
Symptoms that were there all along can become noticeable later. A milder form of ADHD can be managed well until the stresses and demands of adulthood, especially at work, NIMH explains. For women, the UK-led consensus notes that symptoms may become more obvious during times of change in life, that mothers with ADHD may struggle with the added demands of family life, and that hormonal changes with the menstrual cycle, pregnancy and menopause may make symptoms worse. A 2026 Dutch review adds that perimenopause can worsen or unmask symptoms, though there are no randomized trials on treating ADHD at this stage of life.
Symptoms that are truly new in adulthood are a different situation. In a 2018 North American study that assessed young people repeatedly from about age 10 to 25, most people who first screened positive didn’t have late-onset ADHD after careful assessment. Often their symptoms weren’t causing real problems, or they happened only alongside heavy substance use or another mental health condition. A few genuine cases starting in the teen years were found, but none starting in adulthood without other psychiatric history.
Feeling Better on a Stimulant Doesn’t Prove ADHD
Stimulants can make people feel more focused or motivated, and that response doesn’t confirm ADHD. In a 2023 study from Australia, 40 healthy adults without ADHD took two common ADHD stimulants and a wakefulness drug, each on a different day, and a placebo. On the drugs, they worked longer and harder on a complex problem-solving task, but the quality of their work went down. The researchers concluded these “smart drugs” increase motivation while reducing the quality of effort.
People may also believe they’re doing better when tests show little change. In a U.S. study of healthy young adults, an amphetamine-based ADHD stimulant didn’t improve the thinking skills tested for participants in general, yet participants believed it improved their performance more than a placebo did. The authors concluded that its effects on thinking were small at most. There was a hint that participants who scored lower at the start improved on a few tasks.
A UK review that pooled dozens of studies in healthy adults found small improvements in memory recall and sustained attention with one common ADHD stimulant, though not with another. Because people without ADHD can also improve on a stimulant, feeling better on one can’t confirm the diagnosis.
Stimulants also carry real risks. The FDA requires a boxed warning, its most prominent warning, about abuse, misuse and addiction for all prescription stimulants. Misuse can lead to overdose and death, the labels say.
Myth or fact? ADHD in women
Choose an answer for each to see the explanation. Nothing is saved.
1If you have trouble focusing, it's probably ADHD.
Myth. Trouble concentrating also comes with anxiety, depression, poor sleep, trauma, hormonal changes and more. A 2024 U.S. review notes a substantial overlap of symptoms between adult ADHD and other conditions.
2Some women with ADHD are missed in childhood.
Fact. NIMH notes that ADHD symptoms among girls and women are especially likely to have been missed in childhood. A UK-led international consensus adds that inattentive girls are more often missed, because less obvious symptoms are less likely to lead to a referral.
3If a stimulant helps you focus, you must have ADHD.
Myth. In a 2023 study, stimulants increased motivation and effort in healthy adults without ADHD, though the quality of their work on a complex task went down. In a U.S. study, healthy young adults believed a stimulant improved their performance even though testing found no improvement for participants in general.
Living Well With ADHD Symptoms
Whatever is behind your symptoms, these habits may help. They’re practical suggestions, not a substitute for an evaluation, and our post on ADHD strategies beyond medication covers more.
- Build routines and outside systems. Calendars, alarms, lists and a set place for keys and bills take pressure off memory. Our post on why ADHD brains need external structure explains more.
- Protect your sleep. Too little sleep can make it harder to focus, remember things and manage emotions, NHLBI explains.
- Turn off alerts you don’t need, and do one thing at a time when you can.
- Look at your expectations. Notice where they came from, and adjust the ones that aren’t realistic for your life right now. A messy house when you’re raising kids and working full time isn’t a personal failing.
- Track your cycle. If certain weeks are harder, notice the pattern and lighten your schedule when you can.
- Ask for help. Sharing household and caregiving tasks counts as a strategy, not a failure.
Evaluation prep
What to bring up at your evaluation
Tick what you want to bring up with your provider, then copy your list. Nothing is saved or sent.
How Evaluation Works Here
We evaluate ADHD in adults as part of a thorough psychiatric evaluation. Before deciding about ADHD, we look at what else could explain your symptoms:
- Mood first. If depression, anxiety or bipolar symptoms are active, we work on stabilizing them before deciding about ADHD.
- Sleep. We ask about your sleep and may recommend a sleep study.
- Medical health. We recommend a full medical evaluation, with lab work when appropriate (such as thyroid tests, a blood count, iron and vitamin B12), and treating any underlying condition.
- Substances. We may ask for a drug screen. If cannabis or other substances are part of the picture, we reassess after a period without them.
- Childhood information. We look for reliable information about your childhood, such as report cards, school records or someone who knew you as a child. The 2024 review in American Family Physician recommends gathering information from other people who know you.
This follows the requirement in the diagnostic manual used by U.S. clinicians that symptoms aren’t better explained by another condition, as the U.S. review of the diagnostic criteria describes. The American Psychiatric Association notes that an ADHD evaluation may include a referral for a medical evaluation to rule out other medical conditions. A European expert consensus on adult ADHD says the most severe condition is generally treated first. Severe bipolar disorder or severe depression is usually treated first, while milder mood or anxiety problems can be treated at the same time. Substance use is usually treated first or at the same time, in a coordinated plan, according to that consensus and a U.S. addiction medicine guideline.
We’ll also ask about hormonal changes, family history (including ADHD and bipolar disorder), heart conditions and blood pressure, eating disorders or seizures, and your medications. We may use rating scales such as the Adult ADHD Self-Report Scale, which the 2024 review lists as part of an ADHD assessment.
We’ll talk through what we find, including other possible explanations. Depending on what comes up, the evaluation may continue over more than one visit. Your first evaluation is up to 90 minutes in length. Some people need more time, some less, and we take the time you need. Follow-up visits are typically 20 to 30 minutes, and extended follow-ups are available.
One thing we don’t do: formal ADHD or autism testing (neuropsychological testing, done by a psychologist). If testing would help answer your question, we’ll tell you and can share a few resources for where to get it.
Most visits are by secure video, anywhere in New Jersey. Our office is in Mount Laurel, NJ, and in-person visits there are limited and by appointment only; ask our office. Looking for a psychiatrist in New Jersey? Our providers are board-certified psychiatric nurse practitioners (PMHNPs), who provide psychiatric evaluation and medication management.
Our providers never prescribe hormonal treatments, such as birth control or hormone therapy. For those, talk with your gynecologist or primary care provider. If you’d like us to, and with your permission, we can share information with your ob-gyn (or primary care provider) so your care fits together.
How ADHD Is Treated
When the diagnosis is uncertain, symptoms are milder, or something else may explain them, your provider may suggest starting with the basics and then reassessing: skills for organizing tasks and building routines, better sleep, a look at alcohol and cannabis, and help with stress. In a U.S. trial of 86 adults with ADHD who still had symptoms on medication, those who got cognitive behavioral therapy improved more than those who got relaxation training and education, and those who responded or partly responded kept their gains at 6 and 12 months. In children and teens with milder symptoms, an Australian review found that the harms of diagnosis and treatment may outweigh the benefits; it didn’t study adults.
For confirmed ADHD, clinical guidelines recommend stimulants as the first medication option for adults, the 2024 review in American Family Physician notes, and medication may work better when combined with therapy. In studies, stimulants tend to work as well as or better than non-stimulant options: in a large UK-led analysis of short-term trials in adults, one type of stimulant worked better than atomoxetine, and another worked about as well. Stimulants seem to work about as well in females as in males, the UK-led consensus notes, but girls with ADHD are less likely than boys to be prescribed them and tend to start treatment at an older age.
We don’t prescribe controlled medications; if you’d like to consider a stimulant, we’re happy to refer you. Our ADHD care focuses on evaluation, non-controlled medication options when appropriate, and treating the anxiety, depression, sleep and mood concerns that often come with it. If you take a stimulant now, please mention it in your intake packet or call our office, and we’ll talk with you about what we can offer.
Non-controlled options include atomoxetine (Strattera) and viloxazine extended-release (Qelbree), both FDA-approved for ADHD in adults. The 2024 review lists them for adults who can’t take stimulants or who also have anxiety or depression, and some people choose them because they prefer not to take a stimulant. Atomoxetine can start to help within 1 to 2 weeks, but its benefit can keep building for 24 weeks or longer, according to a 2015 review. Bupropion (Wellbutrin), an antidepressant, is sometimes used off-label for ADHD, meaning for a use the FDA hasn’t approved; a Cochrane review (international) found low-quality evidence of a possible benefit in adults. A newer ADHD medication approved in 2026 is a controlled substance, so it isn’t one we prescribe.
Each of these medications has safety points your provider will go over, according to the FDA labels. Viloxazine can raise heart rate and blood pressure, so these are checked before starting, after dose increases and from time to time. It can trigger mania or a mixed episode in people with bipolar disorder, so providers screen for bipolar disorder first. It’s never taken with an MAOI (a type of antidepressant) or within 14 days of stopping one, and because it blocks a liver enzyme (CYP1A2), it can’t be taken with certain medicines that depend on that enzyme. Atomoxetine can rarely cause serious liver injury and can raise heart rate and blood pressure, and its levels can rise with some antidepressants that block another liver enzyme (CYP2D6), such as fluoxetine, paroxetine and bupropion. Bupropion isn’t used in people with a seizure disorder or a current or past diagnosis of bulimia or anorexia, because of a higher risk of seizures.
Both atomoxetine and viloxazine carry a boxed warning about suicidal thoughts and behaviors. Atomoxetine’s boxed warning is based on studies in children and teens, and a similar analysis in adults described on its label didn’t find an increased risk; viloxazine’s applies to adults as well. Either way, your provider will watch for mood changes, especially early on and after dose changes. If you’re in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline), any time, day or night. In an emergency, call 911 or go to the nearest emergency room.
If you’re pregnant or planning a pregnancy, decisions about any medication are made with your provider, weighing the risks and benefits for you. Please don’t stop a medication on your own; some can cause withdrawal symptoms or a return of symptoms if stopped suddenly.
We don’t offer standalone weekly therapy, but we’re happy to help you find a therapist and, with your permission, we’ll coordinate with them.
Is it this or that?
Treating ADHD, or what comes with it?
| ADHD itself | Anxiety or depression alongside it | |
|---|---|---|
| Medication options | Non-controlled options include atomoxetine (Strattera) and viloxazine extended-release (Qelbree), both FDA-approved for adults, and bupropion (Wellbutrin), sometimes used off-label. | Treating anxiety or depression may include an antidepressant, chosen after your evaluation. |
| Other support | Skills for organizing tasks and routines; cognitive behavioral therapy for ADHD has evidence in adults. | Therapy can help too, and we're happy to help you find a therapist. |
| Follow-up | Regular follow-ups to see how things are going and adjust carefully. | Regular follow-ups, especially in the first months of any new medication. |
ADHD itself
- Medication options
- Non-controlled options include atomoxetine (Strattera) and viloxazine extended-release (Qelbree), both FDA-approved for adults, and bupropion (Wellbutrin), sometimes used off-label.
- Other support
- Skills for organizing tasks and routines; cognitive behavioral therapy for ADHD has evidence in adults.
- Follow-up
- Regular follow-ups to see how things are going and adjust carefully.
Anxiety or depression alongside it
- Medication options
- Treating anxiety or depression may include an antidepressant, chosen after your evaluation.
- Other support
- Therapy can help too, and we're happy to help you find a therapist.
- Follow-up
- Regular follow-ups, especially in the first months of any new medication.
Your provider will talk with you about which options fit you. We don't offer standalone weekly therapy, but we're happy to help you find a therapist and, with your permission, we'll coordinate with them. Please don't stop a medication on your own; some can cause withdrawal symptoms or a return of symptoms if stopped suddenly. Sources: NIMH, American Family Physician (2024), Safren 2010, DailyMed: Strattera, DailyMed: Qelbree, Cochrane review (2017). In short-term studies, antidepressants increased suicidal thoughts and behaviors in people up to age 24. Anyone taking one should be watched closely for worsening, especially during the first few months and at times of dosage changes. Don't stop suddenly; talk with your provider first. If you're in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline), any time, day or night. In an emergency, call 911 or go to the nearest emergency room.
Frequently Asked Questions
Can ADHD look like anxiety or depression in women?
It can, and they also often occur together. Both anxiety and depression can make it hard to concentrate. A careful evaluation looks at when your symptoms started and how they show up across your life.
Can you develop ADHD as an adult?
ADHD is defined as starting in childhood. In a North American study with repeated full assessments, most people who first screened positive for late-onset ADHD didn’t have it after careful assessment. Our post Can you develop ADHD as an adult? covers the research.
If a stimulant helps me focus, does that mean I have ADHD?
No. In a 2023 study of healthy adults without ADHD, stimulants increased motivation and effort, though the quality of their work went down. In a separate U.S. study, healthy young adults believed a stimulant improved their performance even though testing found no improvement for participants in general. A response to medication doesn’t confirm the diagnosis.
Can perimenopause or my cycle cause ADHD-like symptoms?
They can cause trouble focusing and memory changes. In perimenopause these changes are common and often improve after menopause, and PMDD can cause trouble thinking or focusing. If your symptoms follow your cycle or started in midlife, bring that to your evaluation.
Is a psychiatric nurse practitioner the same as a psychiatrist?
No. Psychiatrists are medical doctors (MD or DO) who complete a residency in psychiatry. Psychiatric nurse practitioners are advanced practice registered nurses with graduate training in psychiatric care, and ours are board-certified (PMHNP-BC). In New Jersey, both can evaluate, diagnose and prescribe psychiatric medication. Our providers focus on careful evaluation and medication management.
If you’ve spent years working around focus and organization problems, a psychiatric evaluation can help sort out whether ADHD, anxiety, depression or something else is behind them, and medication management can help you stay on track once you have a plan.
This article is for general educational purposes only. It does not constitute medical advice, does not establish a provider-patient relationship, and is not a substitute for individual evaluation, diagnosis, or treatment by a qualified clinician. If you’re in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline), any time, day or night. In an emergency, call 911 or go to the nearest emergency room.
The science: how we checked this
Sources
- Olagunju AE, Ghoddusi F. Attention-Deficit/Hyperactivity Disorder in Adults (U.S.). American Family Physician, 2024
- NIMH: ADHD in Adults: 4 Things to Know
- Kessler RC et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication (U.S.). American Journal of Psychiatry, 2006
- Danielson ML et al. Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults: United States, 2016-2021. CDC, MMWR, 2023
- American Psychiatric Association: What is ADHD? (U.S.)
- Office on Women's Health: Menopause symptoms and relief
- Office on Women's Health: Premenstrual dysphoric disorder (PMDD)
- MedlinePlus: Hyperthyroidism
- MedlinePlus: Iron deficiency anemia
- MedlinePlus: Vitamin B12 deficiency anemia
- NIDDK: Low Blood Glucose (Hypoglycemia)
- Sadek J. Attention Deficit Hyperactivity Disorder Misdiagnosis: Why Medical Evaluation Should Be a Part of ADHD Assessment (Canada). Brain Sciences, 2023
- Chen Q et al. Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study (Sweden). PLoS One, 2018
- Faraone SV et al. Attention-deficit/hyperactivity disorder (U.S.-led, international). Nature Reviews Disease Primers, 2024
- MedlinePlus: Traumatic brain injury
- American Psychiatric Association: DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision), ADHD differential diagnosis, described in our own words
- MedlinePlus: Long COVID
- MedlinePlus: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research (Ireland). Progress in Neurobiology, 2011
- NHLBI: Sleep Deprivation and Deficiency: How Sleep Affects Your Health
- NHLBI: Insomnia, Symptoms
- NHLBI: Sleep Apnea: Symptoms
- NINDS: Restless Legs Syndrome
- NHLBI: Circadian Rhythm Disorders, Symptoms
- Merck Manual Consumer Version: Overview of Allergic Reactions (antihistamine side effects)
- MedlinePlus: Topiramate
- MedlinePlus: Memory loss
- DailyMed: FDA label for alprazolam tablets (a benzodiazepine), adverse reactions and withdrawal
- NIAAA: Alcohol and the Brain: An Overview
- NIDA: Cannabis (Marijuana)
- MedlinePlus: Nicotine and tobacco
- MedlinePlus: Caffeine
- NIMH: Depression
- NIMH: Perinatal Depression
- NIMH: Generalized Anxiety Disorder
- NIMH: Bipolar Disorder
- NIMH: Traumatic Events and Post-Traumatic Stress Disorder (PTSD)
- Kooij JJS et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD (Europe). European Psychiatry, 2019
- ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (U.S.). Journal of Addiction Medicine, 2024
- National Institute on Aging: Coping With Grief and Loss
- Koutsimani P, Montgomery A. Burnout and Cognitive Functioning: Are We Underestimating the Role of Visuospatial Functions? (Greece). Frontiers in Psychiatry, 2022
- Merck Manual Professional Version: Attention-Deficit/Hyperactivity Disorder (ADHD)
- MedlinePlus: Stress and your health
- Stothart C, Mitchum A, Yehnert C. The attentional cost of receiving a cell phone notification (U.S.). Journal of Experimental Psychology: Human Perception and Performance, 2015
- Young S et al. Females with ADHD: an expert consensus statement taking a lifespan approach (UK-led, international). BMC Psychiatry, 2020
- Hartman CA et al. Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit/hyperactivity disorder: A substantive and methodological overview (international). Neuroscience & Biobehavioral Reviews, 2023
- CDC: Diagnosing ADHD
- Epstein JN, Loren RE. Changes in the Definition of ADHD in DSM-5: Subtle but Important (U.S.). Neuropsychiatry (London), 2013
- Wynchank D, Kooij S. Pharmacological management of ADHD in women across perimenopause, menopause and post-menopause (Netherlands). Drugs & Aging, 2026
- Sibley MH et al. Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25 (U.S. and Canada). American Journal of Psychiatry, 2018
- Bowman E et al. Not so smart? "Smart" drugs increase the level but decrease the quality of cognitive effort (Australia). Science Advances, 2023
- Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people (U.S.). Neuropharmacology, 2013
- Roberts CA et al. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine (UK). European Neuropsychopharmacology, 2020
- FDA Drug Safety Communication: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions, May 11, 2023
- FDA label (DailyMed): an example prescription stimulant label, Boxed Warning: Abuse, Misuse, and Addiction
- Safren SA et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial (U.S.). JAMA, 2010
- Kazda L et al. Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review (Australia). JAMA Network Open, 2021
- Cortese S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis (UK-led, international). Lancet Psychiatry, 2018
- FDA label (DailyMed): Strattera (atomoxetine)
- FDA label (DailyMed): Qelbree (viloxazine extended-release)
- Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. Journal of Psychopharmacology, 2015
- Verbeeck W et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults (international). Cochrane Database of Systematic Reviews, 2017
- FDA label (DailyMed): Wellbutrin XL (bupropion extended-release)
How we checked this
- Each claim was checked on Nov 9, 2026 against the original (PubMed abstracts, full texts on PMC, government pages), the round 4 changes again on Nov 10, 2026 (abstracts, full texts and current DailyMed labels), and the round 5 changes on Nov 10, 2026 (the American Psychiatric Association page, MedlinePlus, NIMH, NHLBI, NINDS, NIDDK, NIA, Merck Manual pages, the alprazolam label, PubMed abstracts and the full text of the European consensus).
- Olagunju and Ghoddusi 2024 (U.S.): substantial overlap of symptoms with other conditions; comprehensive history and collateral information; the Adult ADHD Self-Report Scale as an assessment tool; stimulants first-line; medication possibly more effective with psychotherapy; atomoxetine, viloxazine and bupropion for adults unable to take stimulants or with anxiety or depression. NIMH: ADHD symptoms among girls and women especially likely to have been missed in childhood; milder ADHD can be managed until the stresses and demands of adulthood, especially at work. Kessler 2006 (U.S., ages 18 to 44): 12.1% of women and 10.1% of men with adult ADHD treated for ADHD in the past 12 months. CDC MMWR 2023: stimulant fills among commercially insured women rose substantially from 2020 to 2021.
- What else can look like ADHD: the American Psychiatric Association lists learning disorders, mood disorders, anxiety, substance use, head injuries, thyroid conditions and some medications such as steroids as conditions that can mimic ADHD, and says an evaluation may include a referral for a medical evaluation to rule out other medical conditions. Each listed item is linked to a page that names trouble concentrating, thinking, focusing, memory or restlessness (MedlinePlus, NIMH, NHLBI, NINDS, NIDDK, NIAAA, NIDA, NIA, Office on Women's Health, Merck Manuals, the alprazolam label for benzodiazepines) or that lists it among conditions that can be mistaken for ADHD (Sadek 2023, Canada: diabetes; Kooij 2019, Europe: obsessive disorders, borderline personality disorder; Merck: autism; DSM-5-TR differential diagnosis: autism and learning disorders, in our own words). Low blood sugar (NIDDK: confusion) and older antihistamines (Merck: confusion) are described as causing confusion or trouble thinking clearly. Moriarty 2011 (Ireland): impaired attention in chronic pain. Koutsimani 2022 (Greece): cognitive impairments with burnout. Stothart 2015 (U.S.): receiving a phone notification, even without answering it, disrupted performance on an attention task. Media multitasking was left out: a 2017 Dutch meta-analysis (Wiradhany and Nieuwenstein, PMID 28840547) found that a weak link with distractibility disappeared after correcting for small studies. Many of these conditions also occur alongside ADHD: Olagunju and Ghoddusi 2024 (U.S.: ADHD concurrence with anxiety/stress, mood, personality, impulse control and substance use disorders) and Faraone 2024 (U.S.-led, international: numerous co-occurring mental and physical conditions). Chen 2018 (Sweden, national registers): type 2 diabetes about twice as common in adults with ADHD. Young 2020 (UK-led international consensus): household, parenting and caring duties often borne by women. Hartman 2023 (international): pooled odds ratios about 5.0 for anxiety disorders and 4.5 for major depression; no difference by sex in the strength of the link, with anxiety and depression more common in women, as in the general population.
- CDC: no single test for ADHD. Epstein and Loren 2013 (U.S.): adults' difficulty recalling when symptoms began; the diagnostic criteria include exclusionary conditions. Young 2020 (UK-led international consensus): symptoms may become more obvious during transitions and with family demands, and worsen with the menstrual cycle, pregnancy and menopause; stimulant response comparable in females and males; girls prescribed them less often and later. Wynchank 2026 (Netherlands): perimenopause can worsen or unmask symptoms; no randomized trials on treating ADHD in perimenopause. Sibley 2018 (U.S. and Canada): about 95% of those who first screened positive were excluded after careful assessment, mostly for symptoms that weren't impairing or that occurred only with heavy substance use or another condition; most late-onset cases began in adolescence; no evidence of adult-onset ADHD without a complex psychiatric history. Kooij 2019 (European consensus): the most severe disorder is generally prioritized; psychosis, bipolar disorder, substance abuse, severe depression and severe anxiety are usually treated first; milder mood or anxiety disorders can be treated at the same time as ADHD. ASAM/AAAP 2024 guideline (U.S., stimulant use disorder): co-occurring psychiatric disorders treated concurrently with care coordination. The criteria list follows DSM-5-TR (symptoms not better explained by another mental disorder, including substance intoxication or withdrawal); the medical evaluation point follows the American Psychiatric Association page.
- Bowman 2023 (Australia, 40 healthy adults, placebo-controlled): effort up, quality of effort down. Ilieva 2013 (U.S., healthy young adults, double-blind placebo-controlled): no enhancement of any cognitive ability for participants in general, yet participants believed the drug enhanced their performance more than placebo (the belief finding is credited to this study only; Bowman 2023 measured effort and quality, not beliefs); a suggestion that lower-ability participants improved on word recall, embedded figures and Raven's Progressive Matrices; no more than small effects on cognition. Roberts 2020 (UK, meta-analyses of 47 studies in healthy adults): small effects of one stimulant on recall and sustained attention, none for another. FDA 2023 and the current stimulant label: boxed warning for abuse, misuse and addiction; misuse can result in overdose and death. NHLBI: sleep deficiency can cause problems with focusing, remembering and managing emotions. Safren 2010 (U.S., 86 adults already on medication): CBT beat relaxation with educational support; responders and partial responders kept their gains at 6 and 12 months. Cortese 2018 (UK-led network meta-analysis): in adults, one type of stimulant beat atomoxetine head to head; no difference found for the other. Kazda 2021 (Australia): harms may outweigh benefits for children and teens with milder symptoms; adults not studied.
- DailyMed: atomoxetine and viloxazine extended-release FDA-approved for ADHD in adults, neither controlled; boxed-warning scope as stated (the atomoxetine label's adult analysis found no increased risk); viloxazine: heart rate and blood pressure checks, mania and bipolar screening, MAOI and CYP1A2 contraindications; atomoxetine: rare severe liver injury, heart rate and blood pressure, higher levels with strong CYP2D6 inhibitors (fluoxetine, paroxetine studied); Wellbutrin XL: bupropion inhibits CYP2D6 and is contraindicated with seizure disorder or current or prior bulimia or anorexia nervosa. Clemow 2015: atomoxetine can start working within 1 to 2 weeks, with response building for 24 weeks or longer. Cochrane 2017: low-quality evidence for bupropion in adults (off-label).
- How evaluation works here describes our practice. The practical habits and the checklist are suggestions drawn from this article. A newer ADHD medication approved in 2026 is not named; it is a controlled substance (Schedule III). Written in our own words; the quick answer, key takeaways and key points restate this article.
ADHD care at ANK: We evaluate ADHD in adults and can consider non-stimulant medication options when appropriate, along with treating the anxiety, depression, sleep and mood concerns that often come with it. We don't prescribe stimulants or other controlled medications (such as Adderall, Vyvanse, Ritalin or Concerta). Your provider will talk with you about which options fit you.




